Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses.

ABSTRACT: The world was unprepared for coronavirus disease 2019 (COVID-19) and remains ill-equipped for future pandemics. While unprecedented strides have been made developing vaccines and treatments for COVID-19, there remains a need for highly effective and widely available regimens for ambulatory use for novel coronaviruses and other viral pathogens. We posit that a priority is to develop pan-family drug cocktails to enhance potency, limit toxicity, and avoid drug resistance. We urge cocktail development for all viruses with pandemic potential both in the short term (<1 to 2 years) and longer term with pairs of drugs in advanced clinical testing or repurposed agents approved for other indications. While significant efforts were launched against severe acute respiratory syndrome coronavirus 2 (SAR

SUBMITTER: White JM 

PROVIDER: S-EPMC8689562 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature